relative to terminal patients' right to try act.

This bill establishes a legal framework allowing terminally ill patients to access investigational drugs, biological products, or medical devices that have not yet received FDA approval. To qualify, a patient must have a life-limiting condition with no known curative options and must obtain written informed consent from their physician, which includes a waiver of legal liability for any adverse outcomes. The law also protects doctors from license revocation or other penalties if they prescribe these unapproved treatments in good faith. These changes take effect on January 1, 2025, providing a structured pathway for patients to try experimental therapies while defining the specific medical and legal requirements for participation.